Keerthivasan, S., Şenbabaoğlu, Y., Martinez-Martin, N., Husain, B., Verschueren, E., Wong, A., Yang, Y. A., Sun, Y., Pham, V., Hinkle, T., Oei, Y., Madireddi, S., Corpuz, R., Tam, L., Carlisle, S., Roose-Girma, M., Modrusan, Z., Ye, Z., Koerber, J. T., & Turley, S. J. (2021). Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1. Immunity, 54(7), 1511-1526.e8. https://doi.org/10.1016/j.immuni.2021.06.012

Clinical trials will most certainly first include those patients with the highest risk of relapse. However, long term, everything will depend on the risk/ benefit trade off: if an effective, simple, well-tolerated and cost-effective treatment was available (let's imagine a single short low-dose PD1 for any early Melanoma patient) that prevented progression for most patients would be very different from a highly toxic, expensive treatment that doesn't work for everyone (think Ipi 10mg/kg adjuvant)- so everything is in the trade-off